Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Central precocious puberty: current treatment options.

Franco Antoniazzi1, Giorgio Zamboni

  • 1Pediatric Clinic, University of Verona, Verona, Italy. franco.antoniazzi@univr.it

Paediatric Drugs
|September 2, 2004
PubMed
Summary

Central precocious puberty (CPP) is a condition causing early puberty, potentially reducing adult height. Treatment with gonadotropin-releasing hormone (GnRH) agonists is effective and safe for preserving height and well-being.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hajdu-Cheney Syndrome in a Two-Generation Family: Longitudinal Skeletal Progression and Differential Therapeutic Responses in a Mother and Her Son.

International journal of molecular sciences·2026
Same author

Incidence and severity of SARS-CoV-2 infection and vaccine BNT162 side effects in children and adolescents with Noonan Syndrome: a national multicentric study.

Frontiers in pediatrics·2026
Same author

Extracellular Vesicles in Osteogenesis: Comparative Analysis of Stem Cell Sources, Conditioning Strategies, and In Vitro Models Toward Advanced Bone Regeneration.

Cells·2026
Same author

Previously Unreported <i>TMEM38B</i> Variant in Osteogenesis Imperfecta Type XIV: A Case Report and Systematic Review of the Literature.

International journal of molecular sciences·2025
Same author

Congenital hypothyroidism in two children affected by Sotos syndrome: a simple association?

Italian journal of pediatrics·2025
Same author

Mapping the Fat: How Childhood Obesity and Body Composition Shape Obstructive Sleep Apnoea.

Children (Basel, Switzerland)·2025

Area of Science:

  • Pediatric Endocrinology
  • Reproductive Medicine
  • Growth Disorders

Background:

  • Central precocious puberty (CPP) involves early pubertal development before age 8 (girls) or 9 (boys).
  • It leads to accelerated growth, bone maturation, and often a compromised adult height.
  • Diagnosis requires clinical signs, bone age, pelvic ultrasound (girls), and hormonal evaluation.

Purpose of the Study:

  • To review the diagnosis, treatment indications, and outcomes of central precocious puberty.
  • To evaluate the efficacy and safety of gonadotropin-releasing hormone (GnRH) agonist therapy.

Main Methods:

  • Review of clinical signs, bone age, pelvic echography, and hormonal data for diagnosis.
  • Assessment of treatment indications based on auxologic and psychosocial factors.

Related Experiment Videos

  • Analysis of long-term data from GnRH agonist treatment in CPP patients.

    • Main Results:

    • GnRH agonists effectively suppress pituitary gonadal function in CPP patients.
    • Treatment preserves height potential and improves final adult height in many cases, especially in younger children.
    • GnRH agonist therapy demonstrates a good safety profile with minimal adverse effects.

    Conclusions:

    • GnRH agonist treatment is a valuable and safe option for managing central precocious puberty.
    • It helps prevent reduced adult height and psychosocial issues associated with early puberty.
    • Future research may explore combination therapies and GnRH antagonists for improved outcomes.